Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Ovarian Neoplasms

  Free Subscription


Articles published in Gynecol Oncol

Retrieve available abstracts of 294 articles:
HTML format



Single Articles


    June 2025
  1. BOUAZZI M, Zheng G, Wang J, Baandrup L, et al
    Use of statins and risk of ovarian cancer: evidence on effect modification by parity, menopause and endometriosis from nationwide nested case-control studies.
    Gynecol Oncol. 2025;198:130-136.
    PubMed     Abstract available


  2. FU Z, Borho L, Taylor SE, Kelemen LE, et al
    Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis.
    Gynecol Oncol. 2025;198:112-129.
    PubMed     Abstract available


    May 2025
  3. KISTENFEGER Q, Haight PJ, Levine M, Wang H, et al
    The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapy.
    Gynecol Oncol. 2025;198:90-95.
    PubMed     Abstract available


  4. NEWELL A, Andac-Jones E, Gonzalo M, Wright AA, et al
    Patients with advanced ovarian cancer and their experiences and perceptions of sleep disturbance and fatigue across the treatment trajectory: A qualitative study.
    Gynecol Oncol. 2025;198:42-48.
    PubMed     Abstract available


  5. KARLSSON E, Vorobii O, Silins I, Sundstrom Poromaa I, et al
    Splenectomy as an indicator for ovarian cancer spread and complete cytoreduction.
    Gynecol Oncol. 2025;197:121-128.
    PubMed     Abstract available


  6. EVANS E, Dholakia J, Abraham J, Hinton A, et al
    Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors.
    Gynecol Oncol. 2025;197:139-145.
    PubMed     Abstract available


  7. KEVERLINE KJ, Hill B, Hom-Tedla M, Jacobs M, et al
    Impact of mismatch repair (MMR) status on recurrence in high intermediate risk endometrial cancer.
    Gynecol Oncol. 2025;197:116-120.
    PubMed     Abstract available


  8. SUH-BURGMANN E, Hung YY, Finertie H, Zhong H, et al
    Association of endometrial cancer epigenetic mismatch repair deficiency with clinicopathologic factors and survival in a large, diverse community-based cohort.
    Gynecol Oncol. 2025;197:102-109.
    PubMed     Abstract available


  9. THAKER PH, Richardson DL, Hagemann AR, Holloway RW, et al
    OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.
    Gynecol Oncol. 2025 May 2:S0090-8258(25)00797.
    PubMed     Abstract available


    April 2025
  10. LOUKOVAARA M, Pasanen A, Butzow R
    Molecular subgroup-specific prognostic value of semiquantitative lymphovascular space invasion in early-stage endometrioid endometrial cancer.
    Gynecol Oncol. 2025;197:96-101.
    PubMed     Abstract available


  11. POVEDA A, Lheureux S, Colombo N, Cibula D, et al
    Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial.
    Gynecol Oncol. 2025;197:74-82.
    PubMed     Abstract available


  12. YOU B, Anderson C, Cecere SC, Carrot A, et al
    Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial.
    Gynecol Oncol. 2025;197:66-73.
    PubMed     Abstract available


  13. XIE J, Maguire FB, Hofer BM, Cooley JJP, et al
    Disparities in hysterectomy-corrected endometrial cancer incidence trends by histologic subtype among racial/ethnic groups in California, 2012-2019.
    Gynecol Oncol. 2025;197:34-42.
    PubMed     Abstract available


  14. WILKE RN, Wu CF, Kanbergs A, Bercow AS, et al
    Disparities in facility-level adoption of minimally invasive interval debulking surgery for advanced ovarian cancer.
    Gynecol Oncol. 2025;197:11-18.
    PubMed     Abstract available


  15. ZELISSE HS, Snijders MLH, Groenendijk FH, Halfwerk JBG, et al
    The prognostic potential of molecular subtypes including estrogen receptor status in endometrioid ovarian cancer.
    Gynecol Oncol. 2025;196:137-145.
    PubMed     Abstract available


  16. RAIMONDO D, Raffone A, Maletta M, Restaino S, et al
    Hysterectomy or not for borderline ovarian tumor in menopause?
    Gynecol Oncol. 2025;196:152-159.
    PubMed     Abstract available


  17. METTALA T, Joutsiniemi T, Huvila J, Hietanen S, et al
    Genetic predictors of unexpected recurrence in low-risk endometrial cancer: A comprehensive genomic analysis reveals FGFR2 as a risk factor and a rare fatal POLE-mutated recurrence.
    Gynecol Oncol. 2025;196:129-136.
    PubMed     Abstract available


  18. HABLASE R, Steinke J, Aslam A, Jose R, et al
    Anastomotic leakage in colorectal and ovarian cancer resections: A comparative cohort study.
    Gynecol Oncol. 2025;196:121-128.
    PubMed     Abstract available


  19. GONZALEZ-BOSQUET J, Shahi M, Yadav S, Kanwar N, et al
    ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or 2,
    Gynecol Oncol. 2025;196:113-120.
    PubMed     Abstract available


  20. KAHN RM, Murphy K, Patel T, Yeoshoua E, et al
    Three-dimensional volumetric rendering on augmented reality headsets for ovarian cancer cytoreduction planning: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2025;196:107-112.
    PubMed     Abstract available


  21. VARGIU V, Santullo F, Scambia G, Naldini A, et al
    STOMA study SToma-leak ratio in advanced ovarian cancer surgery: Results of a restrictive policy on the use of protective stoMAs.
    Gynecol Oncol. 2025;196:92-98.
    PubMed     Abstract available


  22. HAGHIGHAT R, Ozarowski AL, Liu YL, Frey MK, et al
    MUTYH: Possibly another important gene in ovarian cancer?
    Gynecol Oncol. 2025;196:59-61.
    PubMed    


  23. BRINK GJ, Groeneweg JW, van der Ploeg P, Jonges GN, et al
    Signal transduction pathway activity in adult-type granulosa cell tumor samples.
    Gynecol Oncol. 2025;195:6-11.
    PubMed     Abstract available


    March 2025
  24. MATULONIS UA, Herrstedt J, Oza A, Mahner S, et al
    ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
    Gynecol Oncol. 2025;195:192-199.
    PubMed     Abstract available


  25. ETHIER JL, Shephard C, Granados DP, Dutta N, et al
    Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: An indirect treatment comparison.
    Gynecol Oncol. 2025;196:1-9.
    PubMed     Abstract available


  26. JOHANNET P, Flint M, Chui MH, Konner J, et al
    Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate.
    Gynecol Oncol. 2025;195:173-179.
    PubMed     Abstract available


  27. LI Y, Wu M, Liu Q, Huang C, et al
    Development and validation of an ovarian cancer risk assessment tool for first-degree relatives of patients in the Chinese population.
    Gynecol Oncol. 2025;195:165-172.
    PubMed     Abstract available


  28. SULLIVAN MW, Chui MH, Selenica P, Long Roche K, et al
    Anaplastic carcinoma of the ovary: A single-institution experience and molecular analysis.
    Gynecol Oncol. 2025;195:144-148.
    PubMed     Abstract available


  29. CARUSO G, Kumar A, Langstraat CL, McGree ME, et al
    Racial/ethnic, socioeconomic, and healthcare access disparities in achieving textbook oncologic outcome in advanced ovarian cancer.
    Gynecol Oncol. 2025;195:106-114.
    PubMed     Abstract available


  30. SALINARO J, Singh K, Sands N, Gill V, et al
    Distribution and concordance of HER2 scores in endometrial and ovarian cancer.
    Gynecol Oncol. 2025;195:115-121.
    PubMed     Abstract available


  31. LI X, Wang Z, Man X, Dai X, et al
    Research advances CRISPR gene editing technology generated models in the study of epithelial ovarian carcinoma.
    Gynecol Oncol. 2025;195:34-44.
    PubMed     Abstract available


  32. HICKS A, Borho L, Elishaev E, Berger J, et al
    All-cause mortality and neighborhood social vulnerability among women with ovarian cancer.
    Gynecol Oncol. 2025;195:26-33.
    PubMed     Abstract available


  33. MARCHETTI C, Ergasti R, Capomacchia FM, Giannarelli D, et al
    Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery.
    Gynecol Oncol. 2025;195:16-25.
    PubMed     Abstract available


  34. HERZOG TJ, Liao JB, Finkelstein K, Willmott L, et al
    An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044).
    Gynecol Oncol. 2025;194:145-152.
    PubMed     Abstract available


  35. LI J, Welte T, Calzoncinth K, Vuttaradhi VK, et al
    An inducible FOXL2-dependent mouse model of ovarian adult type granulosa cell tumor.
    Gynecol Oncol. 2025;194:125-130.
    PubMed     Abstract available


  36. ZANNONI GF, Angelico G, Spadola S, Bragantini E, et al
    Chemotherapy Response Score (CRS): A comprehensive review of its prognostic and predictive value in High-Grade Serous Carcinoma (HGSC).
    Gynecol Oncol. 2025;194:1-10.
    PubMed     Abstract available


    February 2025
  37. ASARE A, Previs RA, Spinosa D, Fellman B, et al
    Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.
    Gynecol Oncol. 2025;194:112-118.
    PubMed     Abstract available


  38. ALVERO AB, Wu S, Farrell A, Kim S, et al
    Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis.
    Gynecol Oncol. 2025;194:71-79.
    PubMed     Abstract available


  39. SUN H, Huo X, Bi X, Cao D, et al
    Exosome transmit the ability of migration and invasion in heterogeneous ovarian cancer cells by regulating autophagy via targeting hsa-miR-328.
    Gynecol Oncol. 2025;194:60-70.
    PubMed     Abstract available


  40. MATSUO K, Agarwal J, Chen L, Furey KB, et al
    Histology-specific prognostic significance of isolated tumor cells, micrometastases, and macrometastases in endometrial cancer.
    Gynecol Oncol. 2025;194:51-59.
    PubMed     Abstract available


  41. GAILLARD S, Verma N, Berg M, Harrison J, et al
    A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancer.
    Gynecol Oncol. 2025;194:41-47.
    PubMed     Abstract available


  42. CORTES-SALGADO A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, et al
    HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study.
    Gynecol Oncol. 2025;194:33-40.
    PubMed     Abstract available


  43. KIM J, Park SY, Kim JH, Lee SW, et al
    Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations.
    Gynecol Oncol. 2025;194:25-32.
    PubMed     Abstract available


  44. ROMERO IL, Lengyel E, Wahner Hendrickson AE, Rodriguez GC, et al
    Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial.
    Gynecol Oncol. 2025;194:18-24.
    PubMed     Abstract available


  45. VALENZA C, Mongillo M, Visconti MV, Katrini J, et al
    Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study.
    Gynecol Oncol. 2025;194:11-17.
    PubMed     Abstract available


  46. CORVIGNO S, Fernebro J, Karlsson JS, Mezheieusky A, et al
    High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density.
    Gynecol Oncol. 2025;193:148-155.
    PubMed     Abstract available


    January 2025
  47. MAKI PM, Rubin LH, Krejany EO, Brand A, et al
    What happens after menopause? (WHAM): A prospective controlled study of cognition 24 months after premenopausal risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2025;193:141-147.
    PubMed     Abstract available


  48. TOBONI MD, Dinkins K, Wu S, Mattox T, et al
    Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma.
    Gynecol Oncol. 2025;193:89-97.
    PubMed     Abstract available


  49. WANG H, Zhu J, Zou D, Rao Q, et al
    Multicenter study of ovarian cancer score for diagnosing ovarian cancer.
    Gynecol Oncol. 2025;193:58-64.
    PubMed     Abstract available


  50. RICCIUTI J, Liu Q, Khan ANMNH, Joseph JM, et al
    Prognostic significance of serum complement activation, neutrophil extracellular traps and extracellular DNA in newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2025;193:49-57.
    PubMed     Abstract available


  51. BOGANI G, Moore KN, Ray-Coquard I, Lorusso D, et al
    Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.
    Gynecol Oncol. 2025;193:30-40.
    PubMed     Abstract available


  52. MARINO G, Marchetta L, Negri S, Testa F, et al
    Oncologic and fertility outcomes in patients with juvenile granulosa cell tumor - a retrospective single centre analysis.
    Gynecol Oncol. 2025;192:89-93.
    PubMed     Abstract available


    December 2024
  53. KONUMA M, Ikeda T, Mitoma T, Shirakawa S, et al
    Effectiveness of exercise therapy on chemotherapy-induced peripheral neuropathy in patients with ovarian cancer: A scoping review.
    Gynecol Oncol. 2024;192:155-162.
    PubMed     Abstract available


  54. AZAIS H, Brochard C, Taly V, Benoit L, et al
    Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
    Gynecol Oncol. 2024;192:145-154.
    PubMed     Abstract available


  55. MIRZA MR, Bjorge L, Marme F, Christensen RD, et al
    Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.
    Gynecol Oncol. 2024;192:128-136.
    PubMed     Abstract available


  56. GRAVES S, Sullivan MW, Adkoli A, Zhou Q, et al
    Association between genomic instability score and progression-free/overall survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer.
    Gynecol Oncol. 2024;192:120-127.
    PubMed     Abstract available


  57. PREVIS RA, Strickland KC, Wallen Z, Ko H, et al
    Analysis of real world FRalpha testing in ovarian, fallopian tube, and primary peritoneal cancers.
    Gynecol Oncol. 2024;192:102-110.
    PubMed     Abstract available


    November 2024
  58. SHU T, Liang Y, Zhang S, Sun T, et al
    The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer.
    Gynecol Oncol. 2024;192:94-101.
    PubMed     Abstract available


  59. BORHO L, Elishaev E, Bao R, O'Brien E, et al
    Association of neighborhood social vulnerability with ovarian cancer survival.
    Gynecol Oncol. 2024;192:32-39.
    PubMed     Abstract available


  60. SONAVANE M, Hedlich-Dwyer J, Dal Zotto VL, Tang M, et al
    Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer.
    Gynecol Oncol. 2024;192:65-72.
    PubMed     Abstract available


  61. FRANCIS KE, Simon S, Gebski V, Joly F, et al
    Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
    Gynecol Oncol. 2024;192:50-55.
    PubMed     Abstract available


  62. MOUFARRIJ S, Lakhman Y, Aghajanian C, Abu-Rustum NR, et al
    Evolutionary pathways in early-stage, non-myoinvasive endometrioid endometrial cancers of no specific molecular profile.
    Gynecol Oncol. 2024;192:8-14.
    PubMed     Abstract available


  63. HICKEY M, Nguyen TL, Krejany EO, Domchek SM, et al
    What happens after menopause? (WHAM): Impact of risk-reducing salpingo-oophorectomy on depressive and anxiety symptoms at 24 months.
    Gynecol Oncol. 2024;192:1-7.
    PubMed     Abstract available


  64. LEE AW, Poynor V, Siddiqui S
    Disparities in ovarian cancer survival among ethnic Asian American populations, 2006-2020.
    Gynecol Oncol. 2024;191:292-298.
    PubMed     Abstract available


  65. WEBBER JW, Wollborn L, Mishra S, Vitonis AF, et al
    Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass.
    Gynecol Oncol. 2024;190:124-130.
    PubMed     Abstract available


  66. METCALF CA, Page CE, Stocker BOS, Johnson RL, et al
    Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine.
    Gynecol Oncol. 2024;190:62-69.
    PubMed     Abstract available


  67. TEE XR, Hazard E, Latorre-Esteves E, Kohrn BF, et al
    Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations.
    Gynecol Oncol. 2024;190:18-27.
    PubMed     Abstract available


    October 2024
  68. MOORE KN, Lorusso D, Oaknin A, Oza A, et al
    Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
    Gynecol Oncol. 2024;191:249-258.
    PubMed     Abstract available


  69. GARCIA-DONAS J, Redondo A, Santaballa A, Garrigos L, et al
    Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
    Gynecol Oncol. 2024;191:233-239.
    PubMed     Abstract available


  70. HICKEY M, Trainer AH, Krejany EO, Brand A, et al
    What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO).
    Gynecol Oncol. 2024;191:201-211.
    PubMed     Abstract available


  71. YONEMORI K, Boni V, Min KG, Meniawy TM, et al
    Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.
    Gynecol Oncol. 2024;191:172-181.
    PubMed     Abstract available


  72. OGASAWARA A, Matsushita H, Tan TZ, Shintani D, et al
    Immunological impact of intraperitoneal and intravenous chemotherapy in ovarian cancer, translational analyses of the Phase 3 iPocc trial.
    Gynecol Oncol. 2024;191:124-131.
    PubMed     Abstract available


  73. PINTO P, Moro F, Alcazar JL, Alessi S, et al
    Prediction of non-resectability in tubo-ovarian cancer patients using Peritoneal Cancer Index - A prospective multicentric study using imaging (ISAAC study).
    Gynecol Oncol. 2024;191:132-142.
    PubMed     Abstract available


  74. CARUSO G, Langstraat CL, Kumar A, McGree ME, et al
    Textbook oncologic outcome is an easy-to-use composite quality measure that is strongly associated with survival in advanced-stage ovarian cancer.
    Gynecol Oncol. 2024;191:86-94.
    PubMed     Abstract available


  75. RUSHTON T, Krause HB, Samec T, Elliott A, et al
    Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;191:80-85.
    PubMed     Abstract available


  76. LIAO JB, Jejurikar NS, Hitchcock-Bernhardt KM, Gwin WR, et al
    Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
    Gynecol Oncol. 2024;191:74-79.
    PubMed     Abstract available


    September 2024
  77. WAN S, Gao Y, Wu S, Wang H, et al
    Somatic mutation of targeted sequencing identifies risk stratification in advanced ovarian clear cell carcinoma.
    Gynecol Oncol. 2024;191:56-66.
    PubMed     Abstract available


  78. LI X, Argenta PA, Brown K, Honeyfield K, et al
    Associations of cytomegalovirus infection with cancer-related cognitive impairment and peripheral neuropathy in ovarian cancer survivors.
    Gynecol Oncol. 2024;191:25-30.
    PubMed     Abstract available


  79. JANG EB, Lee AJ, So KA, Lee SJ, et al
    Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment.
    Gynecol Oncol. 2024;191:19-24.
    PubMed     Abstract available


  80. NIEF CA, Long SE, McCleary TL, Kidd E, et al
    Diabetes mellitus complications associated with recurrence of stage I endometrioid endometrial cancer: A single-center retrospective study.
    Gynecol Oncol. 2024;190:298-306.
    PubMed     Abstract available


  81. BROWN J, Miller A, Holman LL, Backes F, et al
    Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
    Gynecol Oncol. 2024;190:283-290.
    PubMed     Abstract available


  82. ADJEI NN, Haas A, Zhao H, Primm KM, et al
    Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021.
    Gynecol Oncol. 2024;190:255-261.
    PubMed     Abstract available


  83. MOKSHAGUNDAM S, McGree ME, Tapia AL, Fought AJ, et al
    Physical and psychological distress amongst patients undergoing neoadjuvant chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2024;190:230-235.
    PubMed     Abstract available


    August 2024
  84. MEERNIK C, Osazuwa-Peters OL, Wilson LE, Joshi A, et al
    Frailty in patients with ovarian cancer and the role of healthcare access, race, and ethnicity.
    Gynecol Oncol. 2024;190:146-152.
    PubMed     Abstract available


  85. QI C, Lyu M, Yao Z, Zhang F, et al
    SVIL promotes ovarian cancer progression and epithelial-mesenchymal transition under hypoxic conditions through the TGF-beta/Smad pathway.
    Gynecol Oncol. 2024;190:167-178.
    PubMed     Abstract available


  86. SKOF E, Stegel V, Dragos VS, Blatnik A, et al
    Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report.
    Gynecol Oncol. 2024;190:104-112.
    PubMed     Abstract available


  87. BARAKZAI SK, Bregar AJ, Del Carmen MG, Eisenhauer EL, et al
    The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study.
    Gynecol Oncol. 2024;190:119-123.
    PubMed     Abstract available


  88. YUNOKAWA M, Kurihara N, Ishizuka N, Kanao H, et al
    Investigating the timing and site of recurrence for ovarian clear cell carcinoma: Analysis of the JGOG/GCIG trial-JGOG 3017-A3.
    Gynecol Oncol. 2024;190:113-118.
    PubMed     Abstract available


  89. LEMIEUX M, Telles R, Goodheart M, Dahmoush L, et al
    Quality of life and survivorship in patients with low-grade ovarian cancer.
    Gynecol Oncol. 2024;190:96-103.
    PubMed     Abstract available


  90. ROSS TL, Na R, Au-Yeung G, DeFazio A, et al
    Are exercise and sitting time during chemotherapy for ovarian cancer associated with treatment-related side-effects, chemotherapy completion and survival?
    Gynecol Oncol. 2024;190:53-61.
    PubMed     Abstract available


  91. YOKOI A, Machida H, Shimada M, Mastuo K, et al
    Efficacy and safety of minimally invasive surgery versus open laparotomy for epithelial ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;190:42-52.
    PubMed     Abstract available


  92. CUN HT, Bernard L, Lande KT, Lawson BC, et al
    Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma.
    Gynecol Oncol. 2024;189:138-145.
    PubMed     Abstract available


  93. VAN DER EERDEN B, de Rooij BH, Schouten LJ, Boll D, et al
    Quality of life among borderline ovarian tumor survivors: A comparison with survivors of early-stage ovarian cancer and a cancer-free population: A cross-sectional population-based PROFILES study.
    Gynecol Oncol. 2024;189:111-118.
    PubMed     Abstract available


  94. STROOT IAS, Bart J, Hollema H, Jalving M, et al
    Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.
    Gynecol Oncol. 2024;187:198-203.
    PubMed     Abstract available


  95. VAN DEN BERG CB, Dasgupta S, Ewing-Graham PC, Bart J, et al
    Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2024;187:113-119.
    PubMed     Abstract available


    July 2024
  96. JOHANSEN G, Lampic C, Floter Radestad A, Dahm-Kahler P, et al
    Health-related quality of life, sexual function, psychological health, reproductive concerns and fertility outcome in young women treated with fertility-sparing surgery for ovarian tumors - A prospective longitudinal multicentre study.
    Gynecol Oncol. 2024;189:101-108.
    PubMed     Abstract available


  97. GUPTA A, O'Cearbhaill RE, Block MS, Hamilton E, et al
    Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial.
    Gynecol Oncol. 2024;189:90-97.
    PubMed     Abstract available


  98. FINCH L, Broach V, Feinberg J, Al-Niaimi A, et al
    ChatGPT compared to national guidelines for management of ovarian cancer: Did ChatGPT get it right? - A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2024;189:75-79.
    PubMed     Abstract available


  99. KAMRAVA MR, Gonzalez-Martin A, Pothuri B, Vergote I, et al
    Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
    Gynecol Oncol. 2024;189:68-74.
    PubMed     Abstract available


  100. POLAN RM, Ali-Fehmi R, Grace AK, Mattei LH, et al
    Occult residual ovarian tissue at the time of minimally invasive risk reducing surgery in women with BRCA mutations.
    Gynecol Oncol. 2024;189:37-40.
    PubMed     Abstract available


  101. ANDRES S, Finch L, Iasonos A, Zhou Q, et al
    Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer.
    Gynecol Oncol. 2024;189:30-36.
    PubMed     Abstract available


  102. MAHONEY DE, Mukherjee R, Thompson J
    Elucidating the influences of social determinants of health on perceived overall health among African American/Black and Hispanic ovarian cancer survivors using the NIH All of Us Research Program.
    Gynecol Oncol. 2024;189:24-29.
    PubMed     Abstract available


  103. MCNAMARA B, Greenman M, Bellone S, Santin LA, et al
    Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.
    Gynecol Oncol. 2024;189:16-23.
    PubMed     Abstract available


  104. RODRIGUEZ GC, Yozwiak M, Nelson OL, Zhang HH, et al
    The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma.
    Gynecol Oncol. 2024;186:110-116.
    PubMed     Abstract available


    June 2024
  105. FUMAGALLI D, Sonik R, De Vitis LA, Rossi V, et al
    Evaluating nutrition in advanced ovarian cancer: which biomarker works best?
    Gynecol Oncol. 2024;188:97-102.
    PubMed     Abstract available


  106. MIRZA MR, Tandaric L, Henriksen JR, Maenpaa J, et al
    NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.
    Gynecol Oncol. 2024;188:103-110.
    PubMed     Abstract available


  107. MANNING-GEIST BL, Sullivan MW, Zhou Q, Iasonos A, et al
    Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
    Gynecol Oncol. 2024;188:52-57.
    PubMed     Abstract available


  108. KOH B, Ryu JY, Noh JJ, Hwang JR, et al
    Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer.
    Gynecol Oncol. 2024;188:60-70.
    PubMed     Abstract available


  109. EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
    Corrigendum to "Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study" [Gynecologic Oncology 164/1(2022) 120-128].
    Gynecol Oncol. 2024;188:58-59.
    PubMed    


  110. BHATNAGAR AR, Ghanem AI, Alkamachi B, Allo G, et al
    The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma.
    Gynecol Oncol. 2024;188:44-51.
    PubMed     Abstract available


  111. BORHO L, Bao R, Elishaev E, Dinkins KD, et al
    Association of allostatic load with overall survival in epithelial ovarian cancer.
    Gynecol Oncol. 2024;186:204-210.
    PubMed     Abstract available


  112. VALABREGA G, Pothuri B, Oaknin A, Graybill WS, et al
    Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
    Gynecol Oncol. 2024;187:128-138.
    PubMed     Abstract available


  113. O'CONNOR RM, Huang DS, Rimel BJ, Kim KH, et al
    Unmet financial needs among patients crowdfunding to support gynecologic cancer care.
    Gynecol Oncol. 2024;186:199-203.
    PubMed     Abstract available


  114. AISAGBONHI O, Ghlichloo I, Hong DS, Roma A, et al
    Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors.
    Gynecol Oncol. 2024;187:241-248.
    PubMed     Abstract available


  115. SCALISE CB, Kincaid K, Thigpen H, Moore J, et al
    A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment.
    Gynecol Oncol. 2024;185:83-94.
    PubMed     Abstract available


    May 2024
  116. FRANCO S, Godley LA
    Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants.
    Gynecol Oncol. 2024;187:235-240.
    PubMed     Abstract available


  117. LOF P, van Soolingen NJ, Piek JMJ, Aarts JWM, et al
    Preferences and considerations for interval cytoreductive surgery in advanced ovarian cancer: The patient's perspective.
    Gynecol Oncol. 2024;187:227-234.
    PubMed     Abstract available


  118. PITIYARACHCHI O, Ansell PJ, Coleman RL, Dinh MH, et al
    Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
    Gynecol Oncol. 2024;187:221-226.
    PubMed     Abstract available


  119. YUAN G, Zhang K, Zheng H, Wu Y, et al
    Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial.
    Gynecol Oncol. 2024;187:212-220.
    PubMed     Abstract available


  120. CARBALLO EV, Kim KH, Penn CA
    Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients.
    Gynecol Oncol. 2024;187:204-211.
    PubMed     Abstract available


  121. LARAJA A, Connor Y, Poulson MR
    The effect of urban racial residential segregation on ovarian cancer diagnosis, treatment, and survival.
    Gynecol Oncol. 2024;187:163-169.
    PubMed     Abstract available


  122. MARCHETTI C, Ataseven B, Perrone AM, Cassani C, et al
    Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status.
    Gynecol Oncol. 2024;187:170-177.
    PubMed     Abstract available


  123. ZENATRI M, Perennec T, Michon C, Gernier F, et al
    Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.
    Gynecol Oncol. 2024;187:139-144.
    PubMed     Abstract available


  124. LIU JF, Xiong N, Wenham RM, Wahner-Hendrickson A, et al
    A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
    Gynecol Oncol. 2024;187:105-112.
    PubMed     Abstract available


  125. ROSATI A, De Rose AM, Gallotta V, Giannarelli D, et al
    Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer.
    Gynecol Oncol. 2024;187:98-104.
    PubMed     Abstract available


  126. FILIPPOVA OT, Boecking K, Broach V, Gardner GJ, et al
    Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2024;187:80-84.
    PubMed     Abstract available


  127. PIEDIMONTE S, Murray C, Atenafu EG, Rouzbahman M, et al
    Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
    Gynecol Oncol. 2024;187:92-97.
    PubMed     Abstract available


  128. LIANG S, Ge H, Zhou S, Tang J, et al
    Prognostic factors of 87 ovarian yolk sac tumor (OYST) patients and molecular characteristics of persistent and recurrent OYST.
    Gynecol Oncol. 2024;187:64-73.
    PubMed     Abstract available


  129. GONZALEZ-MARTIN A, Chung HC, Saada-Bouzid E, Yanez E, et al
    Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
    Gynecol Oncol. 2024;186:182-190.
    PubMed     Abstract available


  130. PAPPAS TC, Roy Choudhury M, Chacko BK, Twiggs LB, et al
    Neural network-derived multivariate index assay demonstrates effective clinical performance in longitudinal monitoring of ovarian cancer risk.
    Gynecol Oncol. 2024;187:21-29.
    PubMed     Abstract available


  131. MACCHIA G, Cilla S, Pezzulla D, Campitelli M, et al
    Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer.
    Gynecol Oncol. 2024;184:16-23.
    PubMed     Abstract available


    April 2024
  132. HOLTZMAN S, McCarthy L, Estevez SL, Lee JA, et al
    Walking the tightrope: Fertility preservation among hereditary breast and ovarian Cancer syndrome Previvors.
    Gynecol Oncol. 2024;186:176-181.
    PubMed     Abstract available


  133. SMITH AJB, O'Brien C, Haggerty A, Ko EM, et al
    "Having cancer is very expensive": A qualitative study of patients with ovarian cancer and PARP inhibitor treatment.
    Gynecol Oncol. 2024;186:170-175.
    PubMed     Abstract available


  134. CHALIF J, Chambers LM, Yao M, Kuznicki M, et al
    Extended-duration antibiotics are not associated with a reduction in surgical site infection in patients with ovarian cancer undergoing cytoreductive surgery with large bowel resection.
    Gynecol Oncol. 2024;186:161-169.
    PubMed     Abstract available


  135. ALGERA MD, van Driel WJ, Slangen BFM, Wouters MWJM, et al
    Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: A population-based study from the Dutch Gynecological Oncology Audit.
    Gynecol Oncol. 2024;186:144-153.
    PubMed     Abstract available


  136. NELSON AT, Harris AK, Watson D, Kamihara J, et al
    Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor Registries.
    Gynecol Oncol. 2024;186:117-125.
    PubMed     Abstract available


  137. EHMANN S, Lam C, Zhou Q, Iasonos A, et al
    Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2024;186:104-109.
    PubMed     Abstract available


  138. ESPINOSA I, D'Angelo E, Prat J
    Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.
    Gynecol Oncol. 2024;186:94-103.
    PubMed     Abstract available


  139. GITTO SB, Ihewulezi CJN, Powell DJ Jr
    Adoptive T cell therapy for ovarian cancer.
    Gynecol Oncol. 2024;186:77-84.
    PubMed     Abstract available


  140. DAHM-KAHLER P, Radestad AF, Holmberg E, Borgfeldt C, et al
    Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study.
    Gynecol Oncol. 2024;186:69-76.
    PubMed     Abstract available


  141. GIEN LT, Enserro DM, Block MS, Waggoner S, et al
    Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
    Gynecol Oncol. 2024;186:61-68.
    PubMed     Abstract available


  142. SAYLOR KW, Fernandes EQ, Adams M, Paraghamian S, et al
    Predictors of germline genetic testing referral and completion in ovarian cancer patients at a Comprehensive Cancer Center.
    Gynecol Oncol. 2024;186:53-60.
    PubMed     Abstract available


  143. KOPELMAN ZA, Tian C, Tumas J, Phippen NT, et al
    Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.
    Gynecol Oncol. 2024;183:103-114.
    PubMed     Abstract available


  144. HOLLIS RL, Elliott R, Dawson JC, Ilenkovan N, et al
    High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;186:42-52.
    PubMed     Abstract available


    March 2024
  145. MONTEMORANO L, Shultz ZB, Farooque A, Hyun M, et al
    TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;186:26-34.
    PubMed     Abstract available


  146. HUANG Y, Rauh-Hain JA, McCoy TH, Hou JY, et al
    Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning.
    Gynecol Oncol. 2024;186:9-16.
    PubMed     Abstract available


  147. PASSARELLI A, Carbone V, Pignata S, Mazzeo R, et al
    Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
    Gynecol Oncol. 2024;183:61-67.
    PubMed     Abstract available


  148. HARTMAN YAW, Kenkhuis MF, Stelten S, Brouwer CG, et al
    Demographic, clinical, and sociocognitive determinants related to physical activity and dietary intake in patients with ovarian cancer: A cross-sectional study.
    Gynecol Oncol. 2024;183:39-46.
    PubMed     Abstract available


  149. LEVINE BJ
    Letter re: Ban et al., A personalized probabilistic approach to ovarian cancer diagnostics.
    Gynecol Oncol. 2024 Mar 15:S0090-8258(24)00155.
    PubMed    


  150. CACCIOTTOLA L, Camboni A, Gatti E, Marbaix E, et al
    Fertility potential and safety assessment of residual ovarian cortex in young women diagnosed with epithelial borderline and early-stage malignant ovarian tumors.
    Gynecol Oncol. 2024;183:15-24.
    PubMed     Abstract available


  151. BYRNE M, Sia TY, Fong C, Khurram A, et al
    Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake.
    Gynecol Oncol. 2024 Mar 14:S0090-8258(24)00144.
    PubMed     Abstract available


  152. RICHARDSON DL, Moore KN, Vergote I, Gilbert L, et al
    Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2024;185:186-193.
    PubMed     Abstract available


  153. NOGUEIRA-RODRIGUES A, Giannecchini GV, Secord AA
    Real world challenges and disparities in the systemic treatment of ovarian cancer.
    Gynecol Oncol. 2024;185:180-185.
    PubMed     Abstract available


  154. CHEN W, Xie J, Gao C, Zhang C, et al
    Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials.
    Gynecol Oncol. 2024;182:108-114.
    PubMed     Abstract available


    February 2024
  155. COSTALES AB, Crane EK, Chambers L, Yao M, et al
    Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MIID-SOC trial.
    Gynecol Oncol. 2024;185:143-147.
    PubMed     Abstract available


  156. SALMAN L, Covens A, Vicus D, Podolsky S, et al
    The role of surgeon specialty in management and survival of malignant ovarian germ cell tumors: A population-based study.
    Gynecol Oncol. 2024;185:138-142.
    PubMed     Abstract available


  157. RONCOLATO F, King MT, O'Connell RL, Lee YC, et al
    Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
    Gynecol Oncol. 2024;185:128-137.
    PubMed     Abstract available


  158. PENFOUND S, Lukey A, Hodgson J, Hopman WM, et al
    Incidence and risk factors of venous and arterial thromboembolic events among patients with ovarian cancer- data from a large Canadian database.
    Gynecol Oncol. 2024;185:116-120.
    PubMed     Abstract available


  159. KRISTENSEN AK, Frandsen CLB, Nohr B, Viuff JH, et al
    Risk of borderline ovarian tumors after fertility treatment - Results from a Danish cohort of infertile women.
    Gynecol Oncol. 2024;185:108-115.
    PubMed     Abstract available


  160. SUIDAN RS, Sun CC, Schneider AK, Lu KH, et al
    Determination of quality of life-related health utilities for surgical complications in ovarian cancer.
    Gynecol Oncol. 2024;185:101-107.
    PubMed     Abstract available


  161. DISIPIO T, Hartel G, Butow P, Webb PM, et al
    Impact of disease recurrence on the supportive care needs of patients with ovarian cancer and their caregivers.
    Gynecol Oncol. 2024;185:33-41.
    PubMed     Abstract available


  162. ABADA E, Kim S, Jang H, Kheil M, et al
    Human epidermal growth factor receptor-2 (HER2) expression in FIGO3 high-grade endometrial endometrioid carcinoma: Clinicopathologic characteristics and future directions.
    Gynecol Oncol. 2024;185:25-32.
    PubMed     Abstract available


  163. CHANG C, Cheng YY, Kamlapurkar S, White S, et al
    GPX3 supports ovarian cancer tumor progression in vivo and promotes expression of GDF15.
    Gynecol Oncol. 2024;185:8-16.
    PubMed     Abstract available


  164. MCNAMARA B, Demirkiran C, Hartwich TMP, Bellone S, et al
    Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
    Gynecol Oncol. 2024 Feb 9:S0090-8258(24)00043.
    PubMed     Abstract available


  165. WESSMAN S, Nister M, Kokaraki G, Pal N, et al
    A comprehensive population-based study of malignant ovarian tumors, including histologic and immunohistochemical review, in children and adolescents 0-19 years old in Sweden between 1970 and 2014.
    Gynecol Oncol. 2024;184:206-213.
    PubMed     Abstract available


  166. SOMASEGAR S, Reddy RA, Chow S, Dorigo O, et al
    Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis.
    Gynecol Oncol. 2024;184:190-197.
    PubMed     Abstract available


  167. POTHURI B, Han S, Chase DM, Heitz F, et al
    Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
    Gynecol Oncol. 2024;184:168-177.
    PubMed     Abstract available


  168. SMITH AJB, Gleason EG, Andriani L, Heintz J, et al
    Variation in telemedicine usage in gynecologic cancer: Are we widening or narrowing disparities?
    Gynecol Oncol. 2024;184:160-167.
    PubMed     Abstract available


  169. TELLES R, Zimmerman MB, Thaker PH, Slavich GM, et al
    Rural-urban disparities in psychosocial functioning in epithelial ovarian cancer patients.
    Gynecol Oncol. 2024;184:139-145.
    PubMed     Abstract available


  170. HARI A, Chang J, Villanueva C, Ziogas A, et al
    Short-term survival analysis of a risk-adjusted model for ovarian cancer care.
    Gynecol Oncol. 2024;184:123-131.
    PubMed     Abstract available


  171. YOON H, Suh DH, Kim K, No JH, et al
    Evaluation of prognostic potential of beta-catenin and L1CAM expression according to endometrial cancer risk group.
    Gynecol Oncol. 2024;184:132-138.
    PubMed     Abstract available


  172. TAYLOR DD, Gercel-Taylor C, Parker LP
    Retraction notice to "Patient-derived tumor reactive antibodies as diagnostic markers for ovarian cancer" [Gynecologic Oncology 115 (2009) 112-120].
    Gynecol Oncol. 2024;181:186.
    PubMed    


  173. VASTA FM, Cormio G, Cassani C, Bergamini A, et al
    Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs.
    Gynecol Oncol. 2024;181:28-32.
    PubMed     Abstract available


    January 2024
  174. SANTORO A, Angelico G, Inzani F, Arciuolo D, et al
    The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations.
    Gynecol Oncol. 2024;184:57-66.
    PubMed     Abstract available


  175. TUBRIDY EA, Eiva MA, Liu F, Omran DK, et al
    CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.
    Gynecol Oncol. 2024;184:74-82.
    PubMed     Abstract available


  176. WEHN AK, Qiu P, Lunceford J, Yarunin A, et al
    Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.
    Gynecol Oncol. 2024;184:67-73.
    PubMed     Abstract available


  177. MOFFAT GT, Kong W, MacKay HJ, McGee J, et al
    Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer.
    Gynecol Oncol. 2024;184:51-56.
    PubMed     Abstract available


  178. MUSACCHIO L, Palluzzi E, Di Napoli M, Lauria R, et al
    Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
    Gynecol Oncol. 2024;184:24-30.
    PubMed     Abstract available


  179. WINKLER SS, Tian C, Casablanca Y, Bateman NW, et al
    Racial, ethnic and country of origin disparities in aggressive endometrial cancer histologic subtypes.
    Gynecol Oncol. 2024;184:31-42.
    PubMed     Abstract available


  180. BAN D, Housley SN, Matyunina LV, McDonald LD, et al
    A personalized probabilistic approach to ovarian cancer diagnostics.
    Gynecol Oncol. 2024;182:168-175.
    PubMed     Abstract available


  181. YANG Q, Peng X, Nian Z, Yuan S, et al
    UCHL-3 as a potential biomarker of ovarian cancer.
    Gynecol Oncol. 2024;182:156-167.
    PubMed     Abstract available


  182. WEIGERT M, Cui XL, West-Szymanski D, Yu X, et al
    5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer.
    Gynecol Oncol. 2024;182:82-90.
    PubMed     Abstract available


  183. TORTORELLA L, Cappuccio S, Giannarelli D, Nero C, et al
    Distribution and prognostic role of BRCA status in elderly ovarian cancer patients.
    Gynecol Oncol. 2024;182:57-62.
    PubMed     Abstract available


  184. LEVINE MD, Wang H, Sriram B, Khan A, et al
    Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
    Gynecol Oncol. 2024;182:51-56.
    PubMed     Abstract available


  185. KAHN RM, Ma X, Gordhandas S, Yeoshoua E, et al
    Regionalizing ovarian cancer cytoreduction to high-volume centers and the impact on patient travel in New York State.
    Gynecol Oncol. 2024;182:141-147.
    PubMed     Abstract available


  186. CASANOVA J, Duarte GS, da Costa AG, Catarino A, et al
    Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2024;182:99-107.
    PubMed     Abstract available


  187. CRISTEA MC, Stewart D, Synold T, Ruel N, et al
    A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRalpha-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer.
    Gynecol Oncol. 2024;182:124-131.
    PubMed     Abstract available


  188. FIFE AJ, Najor AJ, Aspir TB, Haines KE, et al
    Reduced healthcare access contributes to delay of care in endometrial cancer.
    Gynecol Oncol. 2024;182:115-120.
    PubMed     Abstract available


  189. KIM SI, Joung JG, Kim YN, Park J, et al
    Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.
    Gynecol Oncol. 2024;182:7-14.
    PubMed     Abstract available


  190. HANNIBAL CG, Kjaer SK, Galanakis M, Hertzum-Larsen R, et al
    History of autoimmune disease and long-term survival of epithelial ovarian cancer: The extreme study.
    Gynecol Oncol. 2024;182:1-6.
    PubMed     Abstract available


  191. GRESSEL GM, Frey MK, Norquist B, Senter L, et al
    Germline and somatic testing for ovarian Cancer: An SGO clinical practice statement.
    Gynecol Oncol. 2024;181:170-178.
    PubMed     Abstract available


  192. SZAMRETA EA, Monberg MJ, Desai KD, Li Y, et al
    Prognosis and conditional survival among women with newly diagnosed ovarian cancer.
    Gynecol Oncol. 2024;180:170-177.
    PubMed     Abstract available


  193. ALSOMAIRI A, Himayda S, Altelmesani A, Lee YJ, et al
    Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
    Gynecol Oncol. 2024;181:155-161.
    PubMed     Abstract available


    December 2023
  194. WU MF, Cheng XY, Wang DY, Lai YT, et al
    Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial.
    Gynecol Oncol. 2023;181:125-132.
    PubMed     Abstract available


  195. PENVOSE KN, Reed SD, Sepulveda JMG, Mastylak A, et al
    Development and testing of patient-centered education about hormone replacement therapy for women at high genetic risk of breast and ovarian cancer.
    Gynecol Oncol. 2023;181:91-98.
    PubMed     Abstract available


  196. ALTMANN J, Schmitt W, Bashian N, Sehouli J, et al
    A dramatic response to checkpoint inhibitor in a woman with small cell carcinoma of the hypercalcemic type of the ovary.
    Gynecol Oncol. 2023;181:99-101.
    PubMed     Abstract available


  197. CHAN JK, Tian C, Kesterson JP, Lin KY, et al
    Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study.
    Gynecol Oncol. 2023;181:54-59.
    PubMed     Abstract available


  198. KIM JH, Kim SI, Park EY, Kim ET, et al
    Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer.
    Gynecol Oncol. 2023;181:33-39.
    PubMed     Abstract available


  199. BENOIT L, Boudebza A, Bentivegna E, Nguyen-Xuan HT, et al
    What is the most pertinent definition of malnutrition in epithelial ovarian cancer to assess morbidity and mortality?
    Gynecol Oncol. 2023;181:12-19.
    PubMed     Abstract available


  200. RICHARDSON MT, Barry D, Steinberg JR, Thirunavu V, et al
    Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials.
    Gynecol Oncol. 2023;181:1-7.
    PubMed     Abstract available


  201. CHAUHAN S, Langstraat CL, Fought AJ, McGree ME, et al
    Relationship between frailty and nutrition: Refining predictors of mortality after primary cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2023;180:126-131.
    PubMed     Abstract available


  202. YIN X, Zhao S, Zhang M, Xing J, et al
    m6A-modified RIPK4 facilitates proliferation and cisplatin resistance in epithelial ovarian cancer.
    Gynecol Oncol. 2023;180:99-110.
    PubMed     Abstract available


  203. KOSKELA H, Li Y, Joutsiniemi T, Muranen T, et al
    HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma.
    Gynecol Oncol. 2023;180:91-98.
    PubMed     Abstract available


  204. CHASE DM, Annavarapu S, Tseng WY, Shi J, et al
    Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting.
    Gynecol Oncol. 2023;180:79-85.
    PubMed     Abstract available


  205. KAHN RM, Selenica P, Boerner T, Roche KL, et al
    Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
    Gynecol Oncol. 2023;180:35-43.
    PubMed     Abstract available


    November 2023
  206. NASIOUDIS D, Gysler S, Latif N, Cory L, et al
    Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
    Gynecol Oncol. 2023;180:1-5.
    PubMed     Abstract available


  207. PRAISS AM, Hirani R, Zhou Q, Iasonos A, et al
    Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2023;179:169-179.
    PubMed     Abstract available


  208. AGUSTI N, Vidal-Sicart S, Paredes P, Celada-Castro C, et al
    Mapping sentinel lymph nodes in early-stage ovarian cancer (MELISA) trial - a further step towards lymphadenectomy replacement.
    Gynecol Oncol. 2023;179:145-151.
    PubMed     Abstract available


  209. DILLEY J, Gentry-Maharaj A, Ryan A, Burnell M, et al
    Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Gynecol Oncol. 2023;179:123-130.
    PubMed     Abstract available


  210. LIM YH, Dagher C, Abu-Rustum NR, Mueller JJ, et al
    Oncologic outcomes of robot-assisted laparoscopy versus conventional laparoscopy for the treatment of apparent early-stage endometrioid adenocarcinoma of the uterus.
    Gynecol Oncol. 2023;179:152-157.
    PubMed     Abstract available


  211. BAUMANN KE, Siamakpour-Reihani S, Dottino J, Dai Y, et al
    High-fat diet and obesity are associated with differential angiogenic gene expression in epithelial ovarian cancer.
    Gynecol Oncol. 2023;179:97-105.
    PubMed     Abstract available


  212. BESHAR I, Moon AS, Darji H, Liu C, et al
    Aberrant nuclear beta-catenin distribution does not prognosticate recurrences of endometrioid endometrial cancers - A retrospective single-institutional study.
    Gynecol Oncol. 2023;179:85-90.
    PubMed     Abstract available


  213. UCCELLA S, Bosco M, Mezzetto L, Garzon S, et al
    Major vessel resection for complete cytoreduction in primary advanced and recurrent ovarian malignancies: A case series and systematic review of the literature - pushing the boundaries in oncovascular surgery.
    Gynecol Oncol. 2023;179:42-51.
    PubMed     Abstract available


    October 2023
  214. KIM JH, Kim SI, Park EY, Ha HI, et al
    Impact of postoperative residual disease on survival in epithelial ovarian cancer with consideration of recent frontline treatment advances: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;179:24-32.
    PubMed     Abstract available


  215. RANDALL LM, O'Malley DM, Monk BJ, Coleman RL, et al
    Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
    Gynecol Oncol. 2023;178:161-169.
    PubMed     Abstract available


  216. LI S, Zhang X, Zhang T, Zhang R, et al
    Survival outcomes and establishment of a novel risk stratification system in patients with ovarian yolk sac tumors.
    Gynecol Oncol. 2023;178:145-152.
    PubMed     Abstract available


  217. BRZEZINSKA B, Mysona DP, Richardson KP, Rungruang B, et al
    High serum levels of inflammatory markers are associated with early recurrence in patients with high-grade serous ovarian cancer after platinum therapy.
    Gynecol Oncol. 2023;179:1-8.
    PubMed     Abstract available


  218. LEDERMANN JA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al
    Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
    Gynecol Oncol. 2023;178:119-129.
    PubMed     Abstract available


  219. IMTERAT M, Gebers G, Heitz F, Schneider S, et al
    Low anterior resection syndrome and its impact on quality of life of ovarian carcinoma patients: A prospective longitudinal study.
    Gynecol Oncol. 2023;178:96-101.
    PubMed     Abstract available


  220. MCLAUGHLIN HD, Greco P, Straubhar AM, Rolston A, et al
    Implementation of routine venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer.
    Gynecol Oncol. 2023;178:89-95.
    PubMed     Abstract available


  221. KOBEL M, Yang RZ, Kang EY, Al-Shamma Z, et al
    Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
    Gynecol Oncol. 2023;178:80-88.
    PubMed     Abstract available


  222. NGUYEN NT, Raetz A, Montoya D, Schilling V, et al
    Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers.
    Gynecol Oncol. 2023;178:69-79.
    PubMed     Abstract available


  223. JORGENSEN K, Denham C, Kanbergs A, Wu CF, et al
    All-cause and cancer-specific mortality after fertility-sparing surgery for stage IA and IC epithelial ovarian cancer.
    Gynecol Oncol. 2023;178:60-68.
    PubMed     Abstract available


    September 2023
  224. MARSH LA, Kim TH, Zhang M, Kubalanza K, et al
    Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival.
    Gynecol Oncol. 2023;177:173-179.
    PubMed     Abstract available


  225. WRIGHT AA, Poort H, Tavormina A, Schmiege SJ, et al
    Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue.
    Gynecol Oncol. 2023;177:165-172.
    PubMed     Abstract available


  226. DUUS AH, Zheng G, Baandrup L, Faber MT, et al
    Risk of ovarian cancer after salpingectomy and tubal ligation: Prospects on histology and time since the procedure.
    Gynecol Oncol. 2023;177:125-131.
    PubMed     Abstract available


  227. MOUFARRIJ S, Havrilesky L, Jewell EL
    Universal thromboprophylaxis in ovarian cancer patients before and after surgery?
    Gynecol Oncol. 2023;176:A1-A2.
    PubMed    


  228. MCGONIGAL S, Wu R, Grimley E, Turk EG, et al
    A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.
    Gynecol Oncol. 2023;176:139-146.
    PubMed     Abstract available


  229. LIU Y, Chen J, Lu Z, Chang X, et al
    Clinicopathological analysis of patients with molecularly confirmed stage I adult granulosa cell tumors and prediction of recurrence.
    Gynecol Oncol. 2023;176:106-114.
    PubMed     Abstract available


    August 2023
  230. NARAYAN P, Ahsan MD, Webster EM, Perez L, et al
    Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;177:72-85.
    PubMed     Abstract available


  231. AO W, Kim HI, Tommarello D, Conrads KA, et al
    Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment.
    Gynecol Oncol. 2023;177:60-71.
    PubMed     Abstract available


  232. MARJON N, Guerra R, Freeman A, Mak J, et al
    Same day service: A genetic testing station model to improve germline genetic testing in patients with ovarian cancer.
    Gynecol Oncol. 2023;177:53-59.
    PubMed     Abstract available


  233. KIM JH, Park KN, Park EY, Jang MJ, et al
    Impact of warm saline irrigation, hyperthermic intraperitoneal chemotherapy on postoperative pain in primary ovarian cancer from the KOV-HIPEC-01 randomized trial.
    Gynecol Oncol. 2023;177:32-37.
    PubMed     Abstract available


  234. HAGEMANN IS, Deng W, Zaino RJ, Powell MA, et al
    Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.
    Gynecol Oncol. 2023;177:38-45.
    PubMed     Abstract available


  235. PIGNATA S, Bookman M, Sehouli J, Miller A, et al
    Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
    Gynecol Oncol. 2023;177:20-31.
    PubMed     Abstract available


  236. TAYLOR DD, Gercel-Taylor C, Parker LP
    Retraction notice to "Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer" [Gynecologic Oncology Volume 115, Issue 1, October 2009, Pages 112-120].
    Gynecol Oncol. 2023;175:193.
    PubMed    


  237. TAYLOR DD, Gercel-Taylor C
    Retraction notice to "MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer" [Gynecologic Oncology, Volume 110, Issue 1, July 2008, Pages 13-21].
    Gynecol Oncol. 2023;175:192.
    PubMed    


    July 2023
  238. SAITO A, Nishikawa T, Yoshida H, Mizoguchi C, et al
    Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
    Gynecol Oncol. 2023;176:115-121.
    PubMed     Abstract available


  239. MERCADEL AJ, Sanchez-Covarrubias AP, Medina HN, Pinheiro PS, et al
    Intra-racial disaggregation reveals associations between nativity and overall survival in women with endometrial cancer.
    Gynecol Oncol. 2023;176:98-105.
    PubMed     Abstract available


  240. HORVAT N, Causa Andrieu P, Meier A, Ji X, et al
    A preoperative nomogram incorporating CT to predict the probability of ovarian clear cell carcinoma.
    Gynecol Oncol. 2023;176:90-97.
    PubMed     Abstract available


  241. DOS SANTOS MV, Holth A, Lindemann K, Staff AC, et al
    Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma.
    Gynecol Oncol. 2023;176:76-81.
    PubMed     Abstract available


  242. SIA TY, Manning-Geist BL, Ehmann S, Lavery JA, et al
    Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2023;176:69-75.
    PubMed     Abstract available


  243. SHAFA A, Watkins AB, McGree ME, Weroha SJ, et al
    Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?
    Gynecol Oncol. 2023;176:36-42.
    PubMed     Abstract available


  244. O'CEARBHAILL RE, Miller A, Soslow RA, Lankes HA, et al
    A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
    Gynecol Oncol. 2023;176:16-24.
    PubMed     Abstract available


    June 2023
  245. TAYLOR KN, Li A, Manuel M, Rimel BJ, et al
    The association of black race with receipt of hysterectomy and survival in low-risk endometrial cancer.
    Gynecol Oncol. 2023;175:156-162.
    PubMed     Abstract available


  246. COLOMBO N, Gadducci A, Landoni F, Lorusso D, et al
    Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
    Gynecol Oncol. 2023 Jun 22:S0090-8258(23)00306.
    PubMed     Abstract available


  247. MORTON M, Haight PJ, Khadraoui W, Backes F, et al
    "More than a song and dance": Exploration of patient perspectives and educational quality of gynecologic cancer content on TikTok.
    Gynecol Oncol. 2023;175:81-87.
    PubMed     Abstract available


  248. SILBERMAN JN, Bercow AS, Gockley AA, Eisenhauer EL, et al
    Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
    Gynecol Oncol. 2023;175:60-65.
    PubMed     Abstract available


  249. POTHURI B, Blank SV, Myers TK, Hines JF, et al
    Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO).
    Gynecol Oncol. 2023;174:278-287.
    PubMed    


  250. SMITH AJB, Alvarez R, Heintz J, Simpkins F, et al
    Disparities in clinical trial participation in ovarian cancer: A real-world analysis.
    Gynecol Oncol. 2023;175:25-31.
    PubMed     Abstract available


  251. BLANC-DURAND F, Yaniz-Galende E, Llop-Guevara A, Genestie C, et al
    Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer".
    Gynecol Oncol. 2023 Jun 2:S0090-8258(23)00299.
    PubMed    


    May 2023
  252. PEIPERT JD, Goble S, Isaacson J, Tang X, et al
    Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.
    Gynecol Oncol. 2023;175:1-7.
    PubMed     Abstract available


  253. EMBABY A, Kutzera J, Geenen JJ, Pluim D, et al
    WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
    Gynecol Oncol. 2023;174:239-246.
    PubMed     Abstract available


  254. PRAISS AM, Miller A, Smith J, Lichtman SM, et al
    Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
    Gynecol Oncol. 2023;174:213-223.
    PubMed     Abstract available


  255. EURICH K, De La Cruz P, Laguna A, Woodman M, et al
    Multiplex serum immune profiling reveals circulating LAG-3 is associated with improved patient survival in high grade serous ovarian cancer.
    Gynecol Oncol. 2023;174:200-207.
    PubMed     Abstract available


  256. HANVIC B, Lecuru F, Vanacker H, Pautier P, et al
    Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salome study including 469 patients. A TMRG and GINECO group study.
    Gynecol Oncol. 2023;174:190-199.
    PubMed     Abstract available


  257. QIU Y, Zha J, Ma A, Zhou T, et al
    Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2023;174:175-181.
    PubMed     Abstract available


  258. FENG Z, Fu Y, Li R, Li H, et al
    Diffusion-weighted magnetic resonance imaging for the pre-operative evaluation of epithelial ovarian cancer patients.
    Gynecol Oncol. 2023;174:142-147.
    PubMed     Abstract available


  259. THOMSON JP, Hollis RL, van Baal J, Ilenkovan N, et al
    Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.
    Gynecol Oncol. 2023;174:157-166.
    PubMed     Abstract available


  260. WITJES VM, Ligtenberg MJL, Vos JR, Braspenning JCC, et al
    The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?
    Gynecol Oncol. 2023;174:121-128.
    PubMed     Abstract available


  261. KIM SR, Madariaga A, Hogen L, Vicus D, et al
    Safety of fertility sparing management in invasive mucinous ovarian carcinoma.
    Gynecol Oncol. 2023;174:129-132.
    PubMed     Abstract available


  262. MOYETT JM, Howell EP, Broadwater G, Greene M, et al
    Understanding the spectrum of malignant bowel obstructions in gynecologic cancers and the application of the Henry score.
    Gynecol Oncol. 2023;174:114-120.
    PubMed     Abstract available


  263. NEWCOMER MM, Dorayappan KDP, Wagner V, Suarez AA, et al
    Tissue factor as a novel diagnostic target for early detection of ovarian cancer using ultrasound microbubbles.
    Gynecol Oncol. 2023;173:138-150.
    PubMed     Abstract available


  264. ALGERA MD, Slangen BFM, van Driel WJ, Wouters MWJM, et al
    Textbook outcome as a composite outcome measure to compare hospital performances regarding cytoreductive surgery for ovarian cancer: A nationwide population-based study.
    Gynecol Oncol. 2023;174:89-97.
    PubMed     Abstract available


  265. SIA TY, Gordhandas SB, Birsoy O, Kemel Y, et al
    Germline drivers of gynecologic carcinosarcomas.
    Gynecol Oncol. 2023;174:34-41.
    PubMed     Abstract available


  266. SIA TY, Tew WP, Purdy C, Chi DS, et al
    The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
    Gynecol Oncol. 2023;173:130-137.
    PubMed     Abstract available


  267. SAMUEL D, Kwon D, Huang M, Zhao W, et al
    Disparities in refusal of surgery for gynecologic cancer.
    Gynecol Oncol. 2023;174:1-10.
    PubMed     Abstract available


  268. BEDNAR EM, Chen M, Walsh MT Jr, Eppolito AL, et al
    Outcomes of the "BRCA Quality Improvement Dissemination Program": An initiative to improve patient receipt of cancer genetics services at five health systems.
    Gynecol Oncol. 2023;172:106-114.
    PubMed     Abstract available


    April 2023
  269. HANDLEY KF, Mehta S, Martin AL, Biswas S, et al
    Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinoma.
    Gynecol Oncol. 2023;173:114-121.
    PubMed     Abstract available


  270. PEREZ L, Webster E, Bull L, Brewer JT, et al
    Patient perspectives on risk-reducing salpingectomy with delayed oophorectomy for ovarian cancer risk-reduction: A systematic review of the literature.
    Gynecol Oncol. 2023;173:106-113.
    PubMed     Abstract available


  271. GAUDUCHON T, Kfoury M, Lorusso D, Floquet A, et al
    PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
    Gynecol Oncol. 2023;173:98-105.
    PubMed     Abstract available


  272. CHANG X, Tamauchi S, Yoshida K, Yoshihara M, et al
    Downregulating vaccinia-related kinase 1 by luteolin suppresses ovarian cancer cell proliferation by activating the p53 signaling pathway.
    Gynecol Oncol. 2023;173:31-40.
    PubMed     Abstract available


  273. PIGNATA S, Oza A, Hall G, Pardo B, et al
    Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
    Gynecol Oncol. 2023;172:121-129.
    PubMed     Abstract available


  274. SCHWARTZ ZP, Li AJ, Walsh CS, Rimel BJ, et al
    Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes.
    Gynecol Oncol. 2023;173:1-7.
    PubMed     Abstract available


  275. HERNANDEZ-ZEPEDA ML, Munro EG, Caughey AB, Bruegl AS, et al
    Ovarian preservation compared to oophorectomy in premenopausal women with early-stage, low-grade endometrial Cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2023;173:8-14.
    PubMed     Abstract available


    March 2023
  276. BRUCE SF, Wu S, Ribeiro JR, Farrell A, et al
    HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
    Gynecol Oncol. 2023;172:98-105.
    PubMed     Abstract available


  277. AREND R, Dholakia J, Castro C, Matulonis U, et al
    DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
    Gynecol Oncol. 2023;172:82-91.
    PubMed     Abstract available


  278. MUSACCHIO L, Turinetto M, Arenare L, Bartoletti M, et al
    Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
    Gynecol Oncol. 2023;172:72-77.
    PubMed     Abstract available


  279. OLULORO A, Temkin SM, Jackson J, Swisher EM, et al
    What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women.
    Gynecol Oncol. 2023;172:29-35.
    PubMed     Abstract available


  280. OSANN K, Wenzel L, McKinney C, Wagner L, et al
    Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.
    Gynecol Oncol. 2023;171:151-158.
    PubMed     Abstract available


  281. BLANC-DURAND F, Yaniz-Galende E, Llop-Guevara A, Genestie C, et al
    A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
    Gynecol Oncol. 2023;171:106-113.
    PubMed     Abstract available


  282. FOTOPOULOU C
    Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: The evolution of a "pelvic" surgeon.
    Gynecol Oncol. 2023;170:A1-A3.
    PubMed    


  283. LEE SS, Karpel HC, Oh C, Smith J, et al
    Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers.
    Gynecol Oncol. 2023;170:234-240.
    PubMed     Abstract available


  284. LIU YL, Manning-Geist BL, Knezevic A, Deng L, et al
    Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
    Gynecol Oncol. 2023;170:93-101.
    PubMed     Abstract available


    February 2023
  285. HENDRIKSE CSE, Theelen PMM, van der Ploeg P, Westgeest HM, et al
    The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;171:83-94.
    PubMed     Abstract available


  286. JORGENSEN K, Melamed A, Wu CF, Nitecki R, et al
    Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy.
    Gynecol Oncol. 2023 Feb 10:S0090-8258(23)00017.
    PubMed     Abstract available


    January 2023
  287. JAMIESON A, Singh N, Huvila J, Gilks CB, et al
    The continuing evolution of endometrial carcinoma molecular classification: Risk stratification within the No Specific Molecular Profile (NSMP) subtype.
    Gynecol Oncol. 2023 Jan 26:S0090-8258(22)02019.
    PubMed    


  288. HAN C, McNamara B, Bellone S, Harold J, et al
    The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
    Gynecol Oncol. 2023;170:172-178.
    PubMed     Abstract available


  289. MAURICIO D, Bellone S, Mutlu L, McNamara B, et al
    Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
    Gynecol Oncol. 2023;170:38-45.
    PubMed     Abstract available


    September 2022
  290. GERSHENSON DM, Cobb LP, Westin SN, Zhang Y, et al
    Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
    Gynecol Oncol. 2022 Sep 19. pii: S0090-8258(22)00591.
    PubMed     Abstract available


  291. RUSH SK, Lees BF, Huang DS, Peterson MF, et al
    Splenectomy at the time of primary or interval cytoreductive surgery for epithelial ovarian carcinoma: A review of outcomes.
    Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00577.
    PubMed     Abstract available


  292. VREDE SW, Hulsman AMC, Reijnen C, Van de Vijver K, et al
    The amount of preoperative endometrial tissue surface in relation to final endometrial cancer classification.
    Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00570.
    PubMed     Abstract available


    August 2022
  293. BUI A, Gehrig PA, Ghamande S, Rungruang BJ, et al
    Clinical calculator redefines prognosis for high-risk early-stage ovarian cancers and potential to guide treatment in the adjuvant setting.
    Gynecol Oncol. 2022 Aug 30. pii: S0090-8258(22)00551.
    PubMed     Abstract available


  294. MADARIAGA A, Mitchell SA, Pittman T, Wang L, et al
    Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovaria
    Gynecol Oncol. 2022 Aug 30. pii: S0090-8258(22)00544.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.